Ventas, Inc.

NYSE:VTR Stock Report

Market Cap: US$27.2b

Ventas Valuation

Is VTR undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of VTR when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: VTR ($63.55) is trading below our estimate of fair value ($86.12)

Significantly Below Fair Value: VTR is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for VTR?

Key metric: As VTR is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for VTR. This is calculated by dividing VTR's market cap by their current revenue.
What is VTR's PS Ratio?
PS Ratio5.6x
SalesUS$4.80b
Market CapUS$27.20b

Price to Sales Ratio vs Peers

How does VTR's PS Ratio compare to its peers?

The above table shows the PS ratio for VTR vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average3x
STT State Street
2.3x3.1%US$28.2b
TROW T. Rowe Price Group
3.9x3.6%US$26.3b
NTRS Northern Trust
2.8x-0.1%US$21.6b
AMP Ameriprise Financial
3.2x4.8%US$55.3b
VTR Ventas
5.6x7.4%US$27.2b

Price-To-Sales vs Peers: VTR is expensive based on its Price-To-Sales Ratio (5.6x) compared to the peer average (3x).

Price to Sales Ratio vs Industry

How does VTR's PS Ratio compare vs other companies in the US Health Care REITs Industry?

3 CompaniesPrice / SalesEstimated GrowthMarket Cap
DHC Diversified Healthcare Trust
0.4x5.3%US$588.71m
HLTC National Healthcare Properties
0.1xn/aUS$52.72m
GBCS Selectis Health
0.1xn/aUS$4.17m
No more companies available in this PS range
VTR 5.6xIndustry Avg. 5.6xNo. of Companies3PS02.85.68.411.214+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: VTR is good value based on its Price-To-Sales Ratio (5.6x) compared to the US Health Care REITs industry average (5.6x).

Price to Sales Ratio vs Fair Ratio

What is VTR's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

VTR PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio5.6x
Fair PS Ratio5.7x

Price-To-Sales vs Fair Ratio: VTR is good value based on its Price-To-Sales Ratio (5.6x) compared to the estimated Fair Price-To-Sales Ratio (5.7x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst VTR forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$63.55
US$70.21
+10.5%
7.2%US$79.00US$55.00n/a19
Nov ’25US$64.19
US$67.74
+5.5%
7.6%US$76.00US$55.00n/a19
Oct ’25US$63.89
US$65.26
+2.1%
8.8%US$73.00US$55.00n/a19
Sep ’25US$62.11
US$61.68
-0.7%
7.9%US$70.00US$50.00n/a19
Aug ’25US$55.30
US$56.55
+2.3%
8.9%US$69.00US$49.00n/a19
Jul ’25US$50.88
US$54.56
+7.2%
8.8%US$69.00US$49.00n/a18
Jun ’25US$50.26
US$53.51
+6.5%
9.1%US$69.00US$49.00n/a18
May ’25US$43.81
US$52.42
+19.7%
11.0%US$70.00US$46.00n/a19
Apr ’25US$42.86
US$52.84
+23.3%
11.0%US$70.00US$46.00n/a19
Mar ’25US$44.00
US$53.05
+20.6%
11.1%US$72.00US$46.00n/a20
Feb ’25US$47.23
US$54.30
+15.0%
10.4%US$72.00US$47.00n/a20
Jan ’25US$49.84
US$52.63
+5.6%
11.2%US$72.00US$47.00n/a19
Dec ’24US$46.76
US$51.95
+11.1%
10.8%US$72.00US$47.00n/a19
Nov ’24US$42.78
US$52.16
+21.9%
16.7%US$80.00US$44.00US$64.1919
Oct ’24US$42.13
US$53.61
+27.3%
15.7%US$80.00US$47.00US$63.8918
Sep ’24US$43.08
US$52.28
+21.4%
9.5%US$68.00US$45.00US$62.1118
Aug ’24US$48.57
US$53.39
+9.9%
9.3%US$68.00US$45.00US$55.3018
Jul ’24US$47.27
US$54.44
+15.2%
14.4%US$80.00US$45.00US$50.8818
Jun ’24US$43.53
US$53.95
+23.9%
13.9%US$80.00US$45.00US$50.2620
May ’24US$47.67
US$53.71
+12.7%
14.1%US$80.00US$45.00US$43.8121
Apr ’24US$43.35
US$55.20
+27.3%
13.6%US$80.00US$45.00US$42.8620
Mar ’24US$47.54
US$55.05
+15.8%
13.8%US$80.00US$45.00US$44.0021
Feb ’24US$51.66
US$54.20
+4.9%
14.3%US$80.00US$45.00US$47.2322
Jan ’24US$45.05
US$52.89
+17.4%
15.8%US$80.00US$45.00US$49.8422
Dec ’23US$46.37
US$53.20
+14.7%
16.2%US$80.00US$45.00US$46.7622
Nov ’23US$38.41
US$54.70
+42.4%
18.2%US$80.00US$38.00US$42.7822

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

Innovative Industrial Properties

US$3.0b

A self-advised Maryland corporation focused on the acquisition, ownership and management of specialized properties leased to experienced, state-licensed operators for their regulated cannabis facilities.

IIPR

US$107.12

7D

4.8%

1Y

33.3%

Hudson Pacific Properties

US$441.4m

Hudson Pacific Properties (NYSE: HPP) is a real estate investment trust serving dynamic tech and media tenants in global epicenters for these synergistic, converging and secular growth industries.

HPP

US$3.32

7D

-9.8%

1Y

-37.4%

Boardwalk Real Estate Investment Trust

CA$3.8b

Boardwalk REIT strives to be Canada's friendliest community provider and is a leading owner/operator of multi-family rental communities.

BOWF.F

CA$50.23

7D

2.0%

1Y

5.6%